Axsome Therapeutics Inc annual net income for fiscal TTM was -$192 million, a decrease of 4.9% from -$183 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Net Income (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | ($192M) | ($183M) | ($287M) | ($239M) | ($187M) | ($135M) | ($103M) | ($68M) | ($31M) | ($29M) | ($27M) | ($12M) | ($6M) | ($2M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Net Income (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | ($51M) | ($65M) | ($29M) | ($47M) | ($48M) | ($59M) | ($75M) | ($65M) | ($79M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More AXSM metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All AXSM financial statements → Interactive AXSM charts →
About TickerBase · Data methodology & sources · Privacy · Terms